▎药明康德内容团队编辑日前，Biohaven公司在摩根大通医疗健康年会上公布了其蛋白降解药物管线的最新结果。数据显示，其在研疗法BHV-1400在首个人体临床试验中获得积极结果，在最低剂量下只需一次注射，就可在4小时内将致病抗体水平降低60%。基于这 ...

目前，免疫球蛋白A肾病（IgAN）依然是慢性肾脏病（CKD）和终末期肾脏病（ESKD）的主要病因。近年来，一些证据表明，IgAN患者的远期预后要差于既往医生的认知。据报道，IgAN患者10年内的肾脏存活率仅为54%，提示近半数IgAN患者将在10年后 ...

Metabolic Syndrome components significantly associated with prognosis of IgA nephropathy, finds study published in the Scientific Reports.Metabolic syndrome, a cluster of conditions ...

Following this transaction, Peter retains ownership of 106,374 shares in the company. For investors seeking deeper insights, ...

The new data – in rare kidney disease IgA nephropathy (IgAN) – comes from the APPLAUSE-IgAN study, with iptacopan achieving a "clinically meaningful and highly statistically significant ...

Analyst Farzin Haque of Jefferies maintained a Buy rating on Vera Therapeutics (VERA – Research Report), with a price target of $58.00.Invest ...

Climb Bio believes CLYM116 is a potential best-in-class approach to address significant unmet need in patients with IgA nephropathy and other B-cell mediated diseases. This transaction furthers Climb ...

Climb Bio believes CLYM116 is a potential best-in-class approach to address significant unmet need in patients with IgA nephropathy and other B-cell mediated diseases. This transaction furthers ...